Xact Kapitalforvaltning AB raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,954 shares of the medical research company’s stock after acquiring an additional 5,509 shares during the period. Xact Kapitalforvaltning AB’s holdings in Thermo Fisher Scientific were worth $16,321,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Handelsbanken Fonder AB lifted its stake in Thermo Fisher Scientific by 0.3% during the 4th quarter. Handelsbanken Fonder AB now owns 117,765 shares of the medical research company’s stock valued at $22,361,000 after acquiring an additional 300 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in Thermo Fisher Scientific by 5.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 61,263 shares of the medical research company’s stock valued at $11,633,000 after acquiring an additional 2,916 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in Thermo Fisher Scientific by 8.2% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 176,136 shares of the medical research company’s stock valued at $33,445,000 after acquiring an additional 13,347 shares in the last quarter. We Are One Seven LLC bought a new position in Thermo Fisher Scientific during the 4th quarter valued at $190,000. Finally, Compagnie Lombard Odier SCmA lifted its stake in Thermo Fisher Scientific by 12.7% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 7,712 shares of the medical research company’s stock valued at $1,464,000 after acquiring an additional 869 shares in the last quarter. Institutional investors and hedge funds own 87.63% of the company’s stock.

How to Become a New Pot Stock Millionaire

In related news, CFO Stephen Williamson sold 5,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $209.26, for a total value of $1,046,300.00. Following the completion of the sale, the chief financial officer now owns 30,741 shares of the company’s stock, valued at approximately $6,432,861.66. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director William G. Parrett sold 1,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $209.80, for a total value of $209,800.00. The disclosure for this sale can be found here. In the last three months, insiders sold 48,827 shares of company stock valued at $10,606,272. 0.49% of the stock is currently owned by insiders.

Several equities analysts have weighed in on the company. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $240.00 price objective on the stock in a research note on Thursday. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $223.00 to $227.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Leerink Swann restated an “outperform” rating and set a $239.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Thursday, February 1st. They noted that the move was a valuation call. ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Finally, Barclays raised their target price on Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. One analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $222.29.

Shares of Thermo Fisher Scientific stock opened at $212.96 on Thursday. Thermo Fisher Scientific Inc. has a 12-month low of $151.74 and a 12-month high of $226.44. The stock has a market capitalization of $86,271.08, a price-to-earnings ratio of 38.03, a PEG ratio of 1.57 and a beta of 1.15. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.34.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, topping the consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The company had revenue of $6.05 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the firm posted $2.41 EPS. The firm’s revenue for the quarter was up 22.1% on a year-over-year basis. sell-side analysts predict that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be issued a $0.17 dividend. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $0.68 annualized dividend and a yield of 0.32%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 12.14%.

TRADEMARK VIOLATION NOTICE: “Thermo Fisher Scientific Inc. (TMO) Holdings Boosted by Xact Kapitalforvaltning AB” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/thermo-fisher-scientific-inc-tmo-holdings-boosted-by-xact-kapitalforvaltning-ab/1956898.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.